CRSP Stock Climbs As Wall Street Lifts Price Targets

CRISPR Therapeutics AG stocks have been trading up by 10.68 percent following pivotal positive developments in its gene-editing pipeline.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading CRSP

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Citi increased its price target on Crispr Therapeutics from $80 to $82 and reiterated a Buy rating, signaling continued positive expectations for the stock.
Bank of America slightly reduced its price target for Crispr Therapeutics from $86 to $83 while reiterating a Buy rating, noting that encouraging Q1 updates leave its core investment thesis largely unchanged.
Evercore ISI raised its price target on Crispr Therapeutics from $74 to $76 and reiterated an Outperform rating, signaling continued positive expectations for the stock.
Bernstein raised its price target on Crispr Therapeutics to $56 from $50 while reiterating a Market Perform rating, citing a strong biotech tape, healthy M&A and IPO backdrop, and an increasingly supportive FDA environment for earlier-stage companies.

Live Update At 12:32:39 EDT: On Thursday, June 04, 2026 CRISPR Therapeutics AG stock [NASDAQ: CRSP] is trending up by 10.68%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CRISPR Therapeutics AG, ticker CRSP, has been grinding higher on the chart even while the business is still firmly in “build mode.” Over the last couple of weeks, CRSP has climbed from the high‑$40s to around the mid‑$50s, closing near $57.61 on 2026/06/04 after a strong intraday push from a $52.42 open. That is a sharp bounce off the 2026/05/20–21 range, when CRSP was stuck below $50.

Intraday action shows aggressive dip buying. On the latest session, CRSP opened weak, then ripped from the low‑$50s to near $59 by late morning before consolidating in a tight band around $57.50–$58.50. This type of higher‑low, higher‑high structure often tells traders that momentum money is in control.

More Breaking News

Under the hood, CRSP is still a classic clinical‑stage biotech story: Q1 2026 revenue was only about $1.46M, with a net loss of roughly $122.9M and negative margins across the board. Yet the balance sheet is heavy with cash and short‑term investments around $2.44B, current ratio near 18, and modest debt versus equity. For traders, that combination — strong cash runway, high valuation, and no profits — sets up a volatile battleground where sentiment and headlines drive the tape.

Why Traders Are Watching CRSP Right Now

CRSP is front and center on many trading screens because Wall Street just sent a clear, coordinated message: they still like this name. Citi nudged its price target from $80 to $82 and kept a Buy rating on CRISPR Therapeutics AG. That may look like a small move, but for traders it confirms that one of the big banks believes upside remains from current levels.

Evercore ISI backed that story by lifting its target on CRSP from $74 to $76 while reiterating an Outperform rating. When multiple firms refresh their models in the same bullish direction, momentum traders pay attention. It signals that the fundamental narrative behind CRSP — gene‑editing potential, a loaded pipeline, and a thick cash cushion — still justifies prices well above where the stock is trading.

Bank of America’s call on CRISPR Therapeutics AG adds nuance rather than doubt. Yes, they trimmed their target from $86 to $83, but they stuck with a Buy and stressed that encouraging Q1 updates leave the core thesis intact. That reads like fine‑tuning assumptions, not bailing on the story. For short‑term trading, that kind of “down but still Buy” adjustment often removes some froth while keeping the broader bull case alive.

Bernstein sits in the middle. Their CRSP target went from $50 to $56, with a Market Perform stance. They pointed to a strong biotech tape, healthy M&A and IPO flow, and an FDA that looks more open to earlier‑stage players. In plain English, the backdrop for CRISPR Therapeutics AG is getting better, even if Bernstein still sees CRSP as fairly valued versus peers. Put together, these calls build a backdrop where dip buyers in CRSP feel emboldened and short sellers have to be precise.

Conclusion

For active traders, the setup in CRSP blends three things: a strong chart, a speculative balance sheet, and a tightening band of bullish analyst targets. The stock has pushed from sub‑$50 levels to the high‑$50s while big banks mark their targets mostly in the $76–$83 zone, with Bernstein anchoring the lower end near $56. That creates a wide trading range where sentiment can swing the price hard in either direction.

Fundamentally, CRISPR Therapeutics AG is still burning cash, posting a Q1 2026 loss north of $120M, with almost no recurring revenue. But the company carries over $2.4B in cash and short‑term investments and relatively low leverage, giving it time to chase clinical milestones. That runway is a huge part of why firms like Citi, Evercore ISI, and Bank of America stay positive on CRSP despite ugly margins.

For short‑term traders in the Sykes‑style community, this is exactly the kind of name to study: a hot sector, strong catalyst potential, and plenty of range. As Tim Sykes likes to say, “Volatility is opportunity, but only for prepared traders who cut losses fast.” As Tim Bohen, lead trainer with StocksToTrade says, “For me, trading is more about managing risk than finding the next big mover.” CRSP fits that playbook. The key now is to respect the risk, track every headline, and let the price action confirm — or deny — the analyst hype. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!